SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Human Genome Sciences, Inc. (HGSI)
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
1127 105 0 HGSI
Emcee:  Jeffrey Ogbar Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
852Summary of what I understand the results to date are and plans for the TRAIL druSteven Rachbach-5/17/2005
851Certainly, HGSI is worth more after reporting the clinical trials in the past moSteven Rachbach-4/18/2005
850Human Genome Sciences Reports Results of Phase 1 Clinical Trial of HGS-ETR1 in Pnigel bates-4/18/2005
849I had some additional comments on the full albuferon study report: -- The efficSteven Rachbach-4/17/2005
848Some comments I have on the results of the P2a study of Albuferon in interferon-Steven Rachbach-4/14/2005
847Human Genome Sciences Reports Positive Results of Phase 2 Clinical Trial of Albunigel bates-4/14/2005
846Comments about today's report from Lehman (from a post I did for the Yahoo bSteven Rachbach-4/11/2005
845Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-nigel bates-4/6/2005
844If you're talking cancer, then side effects are (to a point) acceptable, evenigel bates-2/28/2005
843Just my opinion: The Biogen/Elan biotech disaster de jour is horrible for develSteven Rachbach-2/28/2005
842CK2 disrupts TRAIL induced apoptosis - Message 21072923nigel bates-2/23/2005
841Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial onigel bates-2/23/2005
840First, the bad: -- Why in God’s name do you need a press release saying you haSteven Rachbach-2/16/2005
839These things take time - Message 21026605 <i>...the research phase of thenigel bates-2/8/2005
838It's no wonder the share price is off 7% as I write this. The market receiveSteven Rachbach-2/8/2005
837This week's lead article in the New England Journal of Medicine reported a sSteven Rachbach-2/3/2005
836[Repifermin versus mucositis in stem cell transplant patients] >>Clinicaltuck-1/5/2005
835a charity.Robin JD Hewitt-12/10/2004
834Human Genome Sciences Completes Patient Enrollment in A Phase 2 Clinical Trial onigel bates-11/30/2004
833A Former Abbott Executive Hired as Human Genome Chief [NYT] By ANDREW POLLACK Doc Bones-11/22/2004
832Human Genome Sciences Announces Agreement With GlaxoSmithKline for Development anigel bates-10/26/2004
831Human Genome Sciences Begins Dosing of Patients in a Phase 2 Clinical Trial of Hnigel bates-10/13/2004
830Comments on the TRAIL data: TRAIL-1 MAB: 39 patients treated in a dose escalatiSteven Rachbach-9/30/2004
829Human Genome Sciences Reports Results of Ongoing Phase 1 Clinical Trials of HGS-nigel bates-9/29/2004
828Human Genome Sciences Reports Initial Results of Phase 1 Clinical Trials of HGS-nigel bates-9/29/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News